Osimertinib Recruiting Phase 2 Trials for Carcinoma NOS Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03778229Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib